A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability

Trial Profile

A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability

Suspended
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Retinal oedema
  • Focus Therapeutic Use
  • Sponsors Taiwan Liposome Company
  • Most Recent Events

    • 30 Apr 2018 Status changed from recruiting to suspended due to strategic review of unblinded data to optimize doses
    • 23 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Jan 2020.
    • 23 Apr 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top